RelB Antibody (A-9): sc-166416

RelB Antibody (A-9) is a mouse monoclonal IgG3 antibody that detects RelB in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). RelB is a crucial member of the NFκB family of transcription factors, playing a significant role in regulating immune responses, inflammation, and cell survival. RelB is primarily located in the nucleus, where RelB forms heterodimers with other NFκB subunits, such as p50, to bind to specific DNA sequences and activate transcription of target genes. Nuclear localization allows RelB to exert effects on gene expression in response to various stimuli, including cytokines and stress signals. RelB heterodimer formation with p50 enhances transcriptional activity, particularly in promoting the expression of genes involved in immune and inflammatory responses. Additionally, RelB undergoes post-translational modifications, such as phosphorylation, which can influence stability and activity, further underscoring RelB importance in cellular signaling pathways. Anti-RelB antibody (A-9) is an essential tool for researchers studying the intricate roles of NFκB signaling in health and disease.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

RelB Antibody (A-9) References:

1. The NFκB paradox: RelB induces and inhibits gene expression.  |  Madge, LA. and May, MJ. 2011. Cell Cycle. 10: 6-7. PMID: 21191180
2. The alternative RelB NF-κB subunit is a novel critical player in diffuse large B-cell lymphoma.  |  Eluard, B., et al. 2022. Blood. 139: 384-398. PMID: 34232979
3. RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion.  |  Zhang, Y., et al. 2022. J Exp Clin Cancer Res. 41: 66. PMID: 35177112
4. RelB is a potential molecular biomarker for immunotherapy in human pan-cancer.  |  Wu, J., et al. 2023. Front Mol Biosci. 10: 1178446. PMID: 37388242
5. RelB-deficient autoinflammatory pathology presents as interferonopathy, but in mice is interferon-independent.  |  Navarro, HI., et al. 2023. J Allergy Clin Immunol. 152: 1261-1272. PMID: 37460023
6. Etiology-independent activation of the LTβ-LTβR-RELB axis drives aggressiveness and predicts poor prognosis in HCC.  |  Scherr, AL., et al. 2024. Hepatology. 80: 278-294. PMID: 37916976
7. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.  |  Kim, SL., et al. 2023. Cell Commun Signal. 21: 315. PMID: 37924094
8. RelB-activated GPX4 inhibits ferroptosis and confers tamoxifen resistance in breast cancer.  |  Xu, Z., et al. 2023. Redox Biol. 68: 102952. PMID: 37944384
9. Lymphotoxin beta-activated LTBR/NIK/RELB axis drives proliferation in cholangiocarcinoma.  |  Xu, K., et al. 2024. Liver Int. 44: 2950-2963. PMID: 39164890
10. Inherited human RelB deficiency impairs innate and adaptive immunity to infection.  |  Le Voyer, T., et al. 2024. Proc Natl Acad Sci U S A. 121: e2321794121. PMID: 39231201

The preferred RelB antibody is RelB Antibody (D-4): sc-48366.